dc.contributor.author | Paredes, Roger | en_US |
dc.contributor.author | Tzou, Philip L. | en_US |
dc.contributor.author | van Zyl, Gert | en_US |
dc.contributor.author | Barrow, Geoff | en_US |
dc.contributor.author | Camacho, Ricardo | en_US |
dc.contributor.author | Carmona, Sergio | en_US |
dc.contributor.author | Grant, Philip M. | en_US |
dc.contributor.author | Gupta, Ravindra K. | en_US |
dc.contributor.author | Hamers, Raph L. | en_US |
dc.contributor.author | Harrigan, P. Richard | en_US |
dc.contributor.author | Jordan, Michael R. | en_US |
dc.contributor.author | Kantor, Rami | en_US |
dc.contributor.author | Katzenstein, David A. | en_US |
dc.contributor.author | Kuritzkes, Daniel R. | en_US |
dc.contributor.author | Maldarelli, Frank | en_US |
dc.contributor.author | Otelea, Dan | en_US |
dc.contributor.author | Wallis, Carole L. | en_US |
dc.contributor.author | Schapiro, Jonathan M. | en_US |
dc.contributor.author | Shafer, Robert W. | en_US |
dc.date.accessioned | 2017-11-21T20:40:04Z | |
dc.date.issued | 2017 | en_US |
dc.identifier.citation | Paredes, R., P. L. Tzou, G. van Zyl, G. Barrow, R. Camacho, S. Carmona, P. M. Grant, et al. 2017. “Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.” PLoS ONE 12 (7): e0181357. doi:10.1371/journal.pone.0181357. http://dx.doi.org/10.1371/journal.pone.0181357. | en |
dc.identifier.issn | | en |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:34375032 | |
dc.description.abstract | Introduction: HIV-1 genotypic resistance test (GRT) interpretation systems (IS) require updates as new studies on HIV-1 drug resistance are published and as treatment guidelines evolve. Methods: An expert panel was created to provide recommendations for the update of the Stanford HIV Drug Resistance Database (HIVDB) GRT-IS. The panel was polled on the ARVs to be included in a GRT report, and the drug-resistance interpretations associated with 160 drug-resistance mutation (DRM) pattern-ARV combinations. The DRM pattern-ARV combinations included 52 nucleoside RT inhibitor (NRTI) DRM pattern-ARV combinations (13 patterns x 4 NRTIs), 27 nonnucleoside RT inhibitor (NNRTI) DRM pattern-ARV combinations (9 patterns x 3 NNRTIs), 39 protease inhibitor (PI) DRM pattern-ARV combinations (13 patterns x 3 PIs) and 42 integrase strand transfer inhibitor (INSTI) DRM pattern-ARV combinations (14 patterns x 3 INSTIs). Results: There was universal agreement that a GRT report should include the NRTIs lamivudine, abacavir, zidovudine, emtricitabine, and tenofovir disoproxil fumarate; the NNRTIs efavirenz, etravirine, nevirapine, and rilpivirine; the PIs atazanavir/r, darunavir/r, and lopinavir/r (with “/r” indicating pharmacological boosting with ritonavir or cobicistat); and the INSTIs dolutegravir, elvitegravir, and raltegravir. There was a range of opinion as to whether the NRTIs stavudine and didanosine and the PIs nelfinavir, indinavir/r, saquinavir/r, fosamprenavir/r, and tipranavir/r should be included. The expert panel members provided highly concordant DRM pattern-ARV interpretations with only 6% of NRTI, 6% of NNRTI, 5% of PI, and 3% of INSTI individual expert interpretations differing from the expert panel median by more than one resistance level. The expert panel median differed from the HIVDB 7.0 GRT-IS for 20 (12.5%) of the 160 DRM pattern-ARV combinations including 12 NRTI, two NNRTI, and six INSTI pattern-ARV combinations. Eighteen of these differences were updated in HIVDB 8.1 GRT-IS to reflect the expert panel median. Additionally, HIVDB users are now provided with the option to exclude those ARVs not considered to be universally required. Conclusions: The HIVDB GRT-IS was updated through a collaborative process to reflect changes in HIV drug resistance knowledge, treatment guidelines, and expert opinion. Such a process broadens consensus among experts and identifies areas requiring further study. | en |
dc.language.iso | en_US | en |
dc.publisher | Public Library of Science | en |
dc.relation.isversionof | doi:10.1371/journal.pone.0181357 | en |
dc.relation.hasversion | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533429/pdf/ | en |
dash.license | LAA | en_US |
dc.subject | Biology and Life Sciences | en |
dc.subject | Microbiology | en |
dc.subject | Microbial Control | en |
dc.subject | Antimicrobial Resistance | en |
dc.subject | Medicine and Health Sciences | en |
dc.subject | Pharmacology | en |
dc.subject | Medical Microbiology | en |
dc.subject | Microbial Pathogens | en |
dc.subject | Viral Pathogens | en |
dc.subject | Immunodeficiency Viruses | en |
dc.subject | HIV | en |
dc.subject | HIV-1 | en |
dc.subject | Pathology and Laboratory Medicine | en |
dc.subject | Pathogens | en |
dc.subject | Organisms | en |
dc.subject | Viruses | en |
dc.subject | Biology and life sciences | en |
dc.subject | RNA viruses | en |
dc.subject | Retroviruses | en |
dc.subject | Lentivirus | en |
dc.subject | Biochemistry | en |
dc.subject | Glycobiology | en |
dc.subject | Glycosylamines | en |
dc.subject | Nucleosides | en |
dc.subject | Enzymology | en |
dc.subject | Enzyme Inhibitors | en |
dc.subject | Protease Inhibitors | en |
dc.subject | Immunology | en |
dc.subject | Vaccination and Immunization | en |
dc.subject | Antiviral Therapy | en |
dc.subject | Antiretroviral Therapy | en |
dc.subject | Protease Inhibitor Therapy | en |
dc.subject | Public and Occupational Health | en |
dc.subject | Preventive Medicine | en |
dc.subject | Molecular Biology | en |
dc.subject | Molecular Biology Techniques | en |
dc.subject | Molecular Biology Assays and Analysis Techniques | en |
dc.subject | Reporter Gene Assay | en |
dc.subject | Health Care | en |
dc.subject | Health Care Policy | en |
dc.subject | Treatment Guidelines | en |
dc.title | Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation | en |
dc.type | Journal Article | en_US |
dc.description.version | Version of Record | en |
dc.relation.journal | PLoS ONE | en |
dash.depositing.author | Kuritzkes, Daniel R. | en_US |
dc.date.available | 2017-11-21T20:40:04Z | |
dc.identifier.doi | 10.1371/journal.pone.0181357 | * |
dash.authorsordered | false | |
dash.contributor.affiliated | Kuritzkes, Daniel | |